__timestamp | Alkermes plc | Merus N.V. |
---|---|---|
Wednesday, January 1, 2014 | 199905000 | 3852327 |
Thursday, January 1, 2015 | 311558000 | 839656 |
Friday, January 1, 2016 | 374130000 | 4478145 |
Sunday, January 1, 2017 | 421578000 | 16432324 |
Monday, January 1, 2018 | 526408000 | 11890871 |
Tuesday, January 1, 2019 | 599449000 | 34110000 |
Wednesday, January 1, 2020 | 538827000 | 35781000 |
Friday, January 1, 2021 | 560977000 | 40896000 |
Saturday, January 1, 2022 | 605747000 | 52200000 |
Sunday, January 1, 2023 | 689751000 | 59836000 |
Unveiling the hidden dimensions of data
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Merus N.V. from 2014 to 2023. Over this period, Alkermes plc consistently outpaced Merus N.V. in SG&A spending, reflecting its larger operational scale. In 2023, Alkermes plc's SG&A expenses surged to nearly 690 million, marking a 245% increase from 2014. In contrast, Merus N.V. exhibited a more modest growth, with expenses rising to approximately 60 million, a 1,455% increase from its 2015 low. This stark contrast highlights Alkermes plc's expansive market strategies compared to Merus N.V.'s more conservative approach. As the industry continues to grow, these financial insights provide a window into the strategic priorities of these companies.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Alkermes plc
Comparing SG&A Expenses: Merck & Co., Inc. vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of AstraZeneca PLC and Alkermes plc
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Merus N.V.
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Alkermes plc
Comparing SG&A Expenses: Summit Therapeutics Inc. vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Alkermes plc
Alkermes plc and CRISPR Therapeutics AG: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Alkermes plc or Vericel Corporation
Comparing SG&A Expenses: Alkermes plc vs Travere Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Merus N.V. vs Ligand Pharmaceuticals Incorporated